TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC grew its position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) by 45.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 200,427 shares of the company’s stock after purchasing an additional 62,542 shares during the period. Geode Capital Management LLC owned 0.66% of TriSalus Life Sciences worth $924,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Highbridge Capital Management LLC purchased a new position in shares of TriSalus Life Sciences during the second quarter valued at approximately $1,184,000. Duquesne Family Office LLC increased its position in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after purchasing an additional 110,966 shares during the last quarter. MSD Partners L.P. purchased a new position in TriSalus Life Sciences during the third quarter worth approximately $184,000. Vestcor Inc purchased a new position in TriSalus Life Sciences during the third quarter worth approximately $108,000. Finally, Walleye Capital LLC purchased a new stake in shares of TriSalus Life Sciences during the 3rd quarter valued at $66,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price target for the company. Canaccord Genuity Group decreased their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Oppenheimer started coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target on the stock. Finally, Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences has an average rating of “Buy” and a consensus target price of $11.79.

TriSalus Life Sciences Stock Up 7.9 %

TLSI opened at $5.16 on Friday. The firm has a market capitalization of $157.34 million, a P/E ratio of -2.07 and a beta of 0.51. The firm’s 50 day moving average is $4.36 and its 200-day moving average is $4.81. TriSalus Life Sciences, Inc. has a 52-week low of $3.50 and a 52-week high of $10.42.

Insider Buying and Selling

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius acquired 62,972 shares of the stock in a transaction on Tuesday, December 17th. The stock was purchased at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the purchase, the insider now directly owns 6,230,748 shares in the company, valued at $24,736,069.56. This trade represents a 1.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have bought 70,012 shares of company stock valued at $281,235 in the last quarter. Company insiders own 32.80% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.